Autologous Killer Cell Therapy in Colon Cancer Patients
NCT ID: NCT03329664
Last Updated: 2021-03-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
20 participants
INTERVENTIONAL
2020-02-09
2022-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer
NCT01929499
Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer
NCT02202928
High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer
NCT03008499
Evaluation of Interest Chemo-oncogramme in Patients With Colonic Adenocarcinoma Stage 4
NCT02305368
Efficacy Study of TKcell in Advanced Colorectal Cancer
NCT00854971
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CIK Intervention plus routine treatment
Patients who receive their routine treatment (chemotherapy, radiation therapy) + Cytokine-induced killer cell infusion
Cytokine-induced killer cell
Immune-cell therapy with CIK cells
Chemotherapy AND/OR Radiation Therapy
Routine treatments for colon cancer patients according to their stage
Control
Patients who receive routine treatments only (chemotherapy, radiation therapy)
Chemotherapy AND/OR Radiation Therapy
Routine treatments for colon cancer patients according to their stage
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cytokine-induced killer cell
Immune-cell therapy with CIK cells
Chemotherapy AND/OR Radiation Therapy
Routine treatments for colon cancer patients according to their stage
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG performance status 0-2
* Adequate cardiac/renal/hepatic function
* Adequate bone marrow function (blood cell count)
Exclusion Criteria
* Patients that have previously participated in another clinical trial
* History of positive test result for HIV, HBV, HCV, HTLV-1, syphilis
* Presence of Active infections
* Patients with immunodeficiencies, autoimmunities, or severe allergies
* Receiving immunosuppressive regimens
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health and Medical Education
UNKNOWN
Digestive Diseases Research Institute, Tehran University of Medical Sciences, Iran
UNKNOWN
Sabz Biomedicals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Naser Ahmadbeigi
Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Naser Ahmadbeigi, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Cell-based Therapies Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gene Therapy Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences
Tehran, , Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Autologous Killer cell therapy
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.